Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leuke...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Wugen, Inc.
Collaborators
NCT04972942 · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more
NCT05674175 · B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
NCT05376111 · T-cell Acute Lymphoblastic Leukemia, Recruiting
City of Hope
Duarte, California
Children's Hospital Los Angeles
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions